These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
705 related articles for article (PubMed ID: 34861327)
1. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review. Conlon JM; O'Harte FPM; Flatt PR Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327 [TBL] [Abstract][Full Text] [Related]
2. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703 [TBL] [Abstract][Full Text] [Related]
3. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice. Graham GV; McCloskey A; Abdel-Wahab YH; Conlon JM; Flatt PR Mol Cell Endocrinol; 2020 Jan; 499():110584. PubMed ID: 31539596 [TBL] [Abstract][Full Text] [Related]
4. Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Peptides; 2018 Dec; 110():19-29. PubMed ID: 30391422 [TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651 [TBL] [Abstract][Full Text] [Related]
6. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting analogues of lamprey GLP-1 and paddlefish glucagon on alpha- to beta-cell transdifferentiation in an insulin-deficient transgenic mouse model. Graham GV; Conlon JM; Moffett RC; Abdel-Wahab YH; Flatt PR J Pept Sci; 2021 Aug; 27(8):e3328. PubMed ID: 33843129 [TBL] [Abstract][Full Text] [Related]
8. An update on peptide-based therapies for type 2 diabetes and obesity. Bailey CJ; Flatt PR; Conlon JM Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818 [TBL] [Abstract][Full Text] [Related]
9. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
10. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Irwin N; Hunter K; Montgomery IA; Flatt PR Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064 [TBL] [Abstract][Full Text] [Related]
11. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097 [TBL] [Abstract][Full Text] [Related]
12. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice. Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466 [TBL] [Abstract][Full Text] [Related]